DNA-PKcs inhibitors work by blocking the kinase activity of DNA-PKcs, thereby preventing the phosphorylation of its substrates. This inhibition disrupts the NHEJ pathway, leading to impaired DNA repair. As a result, cancer cells accumulate DNA damage and are pushed towards apoptosis or other forms of cell death.
